US 12,012,454 B2
Anti-tumor antigen nanobody and nucleic acid encoding sequence thereof, and uses of the same
Der-Yang Cho, Taichung (TW); Shao-Chih Chiu, Taichung (TW); Shi-Wei Huang, Taichung (TW); Chih-Ming Pan, Taichung (TW); Mei-Chih Chen, Taichung (TW); Yu-Chuan Lin, Taichung (TW); and Yeh Chen, Taichung (TW)
Assigned to CHINA MEDICAL UNIVERSITY HOSPITAL, Taichung (TW)
Filed by China Medical University Hospital, Taichung (TW)
Filed on Mar. 11, 2022, as Appl. No. 17/692,599.
Claims priority of provisional application 63/165,266, filed on Mar. 24, 2021.
Prior Publication US 2022/0306747 A1, Sep. 29, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2833 (2013.01) [A61P 35/00 (2018.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/76 (2013.01)] 17 Claims
OG exemplary drawing
 
1. An anti-HLA-G nanobody that specifically binds to a human leukocyte antigen-G (HLA-G), wherein the anti-HLA-G nanobody consists of the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, wherein the amino acid sequence of SEQ ID NOs: 1, 2, and 3 are a heavy chain variable domain (VHH) of the anti-HLA-G nanobody, wherein the anti-HLA-G nanobody is separated and purified by gel filtration chromatography.